O
Ore Holdings
Acquiring and developing clinical-stage drug development companies
About Ore Holdings
Ore Holdings, Inc. operates as a drug asset development company focused on acquiring and advancing clinical-stage drug development entities to enhance their portfolio value. Previously known as Ore Pharmaceutical Holdings Inc., the company is engaged in the development and monetization of pharmaceutical assets, including compounds in-licensed from major pharmaceutical corporations. These compounds are aimed at treating a range of conditions such as Inflammatory Bowel Disease, other gastrointestinal indications, autoimmune and inflammatory diseases, cardiovascular disease, and cognitive disorders. Headquartered in New York, NY, the private company's primary industry is private equity.
Source: Dealroom company dataAt a glance
- Founded
- 1995
- Headquarters
- New York City, United States
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
- TMTekla Capital Management
- OPOxford Bioscience Partners
GeneChem
Goldman Sachs
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ore Holdings on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ore Holdings on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.